Brainstorm Cell Therapeutics, Inc.

Brainstorm Cell Therapeutics, Inc.

Brainstorm Cell Therapeutics, Inc.

Overview
Date Founded

2006

Headquarters

605 3rd Avenue,34th floor,New York, NY 10158

Type of Company

Public

Employees (Worldwide)

31

Industries

Biotechnology
Medical Support Services
Hospitals & Patient Services
Pharmaceuticals

Company Description

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Contact Data
Trying to get in touch with decision makers at Brainstorm Cell Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Executive Officer

Chief Financial Officer, Treasurer & Executive Vice President

Chief Operating Officer & Chief Medical Officer

Chief Commercial Officer

Executive Vice President & Chief Business Officer

Head of Clinical Operations

Chief Scientific Advisor

Vice President Scientific & Regulatory Affairs

Vice President Cell Production

Board of Directors

Former Executive Vice President-Research & Development at Savicell Diagnostic Ltd.

Executive Vice President, Early Development & Chief Scientific Officer at Zymeworks, Inc.

Co-Founder at resTORbio, Inc.

Chief Scientific Officer at RedHill Biopharma Ltd.

Partner at Davidoff Hutcher and Citron LLP

Paths to Brainstorm Cell Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Brainstorm Cell Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Sabby Capital focuses on investments in the healthcare sector.

Details Hidden

Cold Creek Capital seeks to construct diversified portfolios of high quality companies with strong financials, exceptional management teams and sustainable competitive advantages. The firm employs a top-down and bottom-up investment process that integrates traditional fundamental analysis and risk management tools. After they assess the client's objectives and risk profile, they establish a target asset allocation profile for the client. The asset allocation targets may include ranges around the targets for each asset class. Cold Creek Capital then selects investment products within each asset class, primarily, but not limited to, no-load mutual funds and/or ETFs, to implement their strategies and achieve the targeted asset allocation. Cold Creek Capital's investment products include: Mid-Cap Growth, Small-Cap Growth and Concentrated Growth. The firm also builds customized portfolios to meet client-specific objectives.

Details Hidden

Cold Creek Capital seeks to construct diversified portfolios of high quality companies with strong financials, exceptional management teams and sustainable competitive advantages. The firm employs a top-down and bottom-up investment process that integrates traditional fundamental analysis and risk management tools. After they assess the client's objectives and risk profile, they establish a target asset allocation profile for the client. The asset allocation targets may include ranges around the targets for each asset class. Cold Creek Capital then selects investment products within each asset class, primarily, but not limited to, no-load mutual funds and/or ETFs, to implement their strategies and achieve the targeted asset allocation. Cold Creek Capital's investment products include: Mid-Cap Growth, Small-Cap Growth and Concentrated Growth. The firm also builds customized portfolios to meet client-specific objectives.

Recent Transactions
Details Hidden

Brainstorm Cell Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Brainstorm Cell Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Brainstorm Cell Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors
Investment Advisor

Advised onBrainstorm Cell Therapeutics, Inc. raised money in a private placement transaction

Auditor

Advised onBrainstorm Cell Therapeutics, Inc. issued Units

Underwriter

Advised onBrainstorm Cell Therapeutics, Inc. issued Units

Advisors & Consultants
Publicist

Founding Partner at LifeSci Capital LLC

Consultant

Head-Health Policy, Health Care Management & Health Economics Department at The Hebrew University of Jerusalem

Publicist

Senior Vice President of US Media Relations at Hill+Knowlton Strategies LLC

Key Stats and Financials As of 2018
Market Capitalization
$83M
Total Enterprise Value
$63.9M
Earnings Per Share
$-0.7
Revenue
$0
Net Profit
$-14M
EBITDA
$-14M
Total Debt
$0
Total Equity
$5.02M
TEVNet Income
-4.58x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Investors
Details Hidden

The California Institute for Regenerative Medicine ("The Institute" or "CIRM") was established in early 2005 following the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The mission of CIRM is to support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury.

Suppliers
Tel Aviv University Schools & Student Services | Ramat Aviv, TA

Tel Aviv University (TAU) (Hebrew: ?????????? ???????? Universitat Tel Aviv) is a public university located in Ramat Aviv, Tel Aviv, Israel. With nearly 30,000 students, TAU is Israel's largest university. Located in Israel's cultural, financial and industrial core, Tel Aviv University is a major center of teaching and research, comprising 9 faculties, 27 schools, 98 departments and 128 research institutes and centers. Its origins go back to 1956, when three research institutes – the Tel Aviv School of Law and Economics, the Institute of Natural Sciences, and the Institute of Jewish Studies – joined together to form the University of Tel Aviv. Initially operated by the Tel Aviv municipality, the university was granted autonomy in 1963. The university also maintains academic supervision over the Center for Technological Design in Holon, the New Academic College of Tel Aviv-Yaffo, and the Afeka College of Engineering in Tel Aviv. The Wise Observatory is located in Mitzpe Ramon.

Dana-Farber Cancer Institute, Inc. IT Consulting & Services | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

TO PROVIDE MEDICAL CARE FOR PEOPLE WITH CANCER AND OTHER CATASTROPHIC DISEASES AS PART OF A COORDINATED HEALTHCARE DELIVERY SYSTEM OPERATED BY CITY OF HOPE.

Competitors
Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Ionis Pharmaceuticals, Inc. Pharmaceuticals - Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Brainstorm Cell Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Brainstorm Cell Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Brainstorm Cell Therapeutics, Inc..